Su-Ying Liang, PhD

Articles

Genomic Testing and Therapies for Breast Cancer in Clinical Practice

May 15, 2011

Despite almost universal testing for human-epidermal-growth-factor-receptor-2 (HER2), many women with a HER2-positive cancer may not receive trastuzumab. Fewer women received the newer gene-expression-profile (GEP) test.